---
title: "carmena trial"
slug: "carmena-trial"
date: "2024-01-03"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Treatment principles-of-renal-cell-carcinoma]]

# carmena trial

- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
  List of authors.

MÃ‰JEAN, Arnaud, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. New England Journal of Medicine, 2018, 379.5: 417-427.

- The median overall survival was 18.4 months in the sunitinib-alone group and 13.9 months in the nephrectomy-sunitinib group.
- No significant differences in response rate or progression-free survival were observed. Adverse events were as anticipated in each group.
